Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
The Department of Health and Human Services is looking to replace lab animals with AI models. Even more bullish on AI is the new boss at the Centers for Medicare and Medicaid Services.
GenAI initiatives are complex and—in some cases—costly. “As such, the main rationale for pursuing them needs to be business growth, not workforce reductions.”
The authors of the survey report note that AI tools mentioned by respondents run the gamut from automated appointment reminders to dynamic “care gap” messaging.
Some AI decision-support models have a proclivity for recommending aggressive care pathways. And doing so on the basis of patient demographics, not medical necessity.
In exclusive interviews, HealthExec spoke with the American Cancer Society about rising cancer rates, and a virtual provider service that's working to bolster struggling oncology staff.
A data analysis from the Physicians Advocacy Institute and Avalere Health found corporate buyouts are leaving patients in low-population areas with fewer options, as doctors are opting to go elsewhere.
Many if not most hospitals and other provider organizations take a decided interest in what their peer institutions are doing with AI. A major motivator for the keen curiosity is gauging how well one is keeping up with the Joneses. So to speak.